logo
  • About
  • R&D
  • Pipeline
  • Investors
  • News
  • Contact
  • Primary Sclerosing Cholangitis
  • Nonalcoholic Steatohepatitis (NASH)
  • (NASH) דלקת כבד על רקע שומני
Investor Relations

Investor Relations

  • Overview
  • News & Events
    • News
    • Events
    • Presentations
    • Contact IR
    • Email Alerts
  • Financials & Filings
    • SEC Filings
    • Annual Reports
    • Quarterly Results
  • Stock
    • Stock Quote & Chart
    • Historical Stock Price
    • Analyst Coverage
  • Corporate Governance
    • Board Committees
    • Board of Directors
    • Leadership
    • Documents
    • SEC Filings

    • Annual Reports

    • Quarterly Results

NASDAQCMMB
YearTrailing 12-MonthsCalendar Year 2023Calendar Year 2022Calendar Year 2021Calendar Year 2020Calendar Year 2019Calendar Year 2018Calendar Year 2013Calendar Year 2012Calendar Year 2011
ViewAll FilingsAnnual FilingsQuarterly FilingsCurrent FilingsRegistration StatementsSection 16Mergers & AcquisitionsProxy & Information StatementsOther
FormDescriptionDateFormat
ARSAn annual report to security holders.Mar 21, 2023Open An annual report to security holders. in HTML.Open An annual report to security holders. in DOC file.Open An annual report to security holders. in PDF file.Open An annual report to security holders. in XLS file.
10-KAnnual report which provides a comprehensive overview of the company for the past yearMar 20, 2023Open Annual report which provides a comprehensive overview of the company for the past year in HTML.Open Annual report which provides a comprehensive overview of the company for the past year in DOC file.Open Annual report which provides a comprehensive overview of the company for the past year in PDF file.Open Annual report which provides a comprehensive overview of the company for the past year in XLS file.Open Annual report which provides a comprehensive overview of the company for the past year in XBLR Viewer.Open Annual report which provides a comprehensive overview of the company for the past year in XBLR file.

Investor Relations

Chemomab Therapeutics Ltd.

Kiryat Atidim, Building 7
Tel Aviv, Israel 6158002

Follow us on

Subscribe to Alerts

Irina Koffler

LifeSci Advisors, LLC

IR@Chemomab.com

Phone: +1-917-734-7387

Barbara Lindheim

Consulting Vice President

Investor & Public Relations

barbara@chemomab.com

Phone: +1-917-355-9234

Copyright © Chemomab. All rights reserved.

Privacy Policy Terms of Service

Designed and built by Studio Praktik